Erythropoietin and subarachnoid hemorrhage

J Neurosurg. 2010 Mar;112(3):699-700. doi: 10.3171/2009.8.JNS09961.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Animals
  • Brain Ischemia / drug therapy
  • Brain Ischemia / physiopathology
  • Clinical Trials, Phase II as Topic
  • Disease Models, Animal
  • Erythropoietin / administration & dosage
  • Erythropoietin / adverse effects
  • Erythropoietin / therapeutic use*
  • Humans
  • Neuroprotective Agents / administration & dosage
  • Neuroprotective Agents / adverse effects
  • Neuroprotective Agents / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / adverse effects
  • Recombinant Proteins / therapeutic use
  • Subarachnoid Hemorrhage / drug therapy*
  • Subarachnoid Hemorrhage / physiopathology
  • Time Factors

Substances

  • Neuroprotective Agents
  • Recombinant Proteins
  • Erythropoietin